Bioethics News

AstraZeneca Launches Project to Sequence 2 Million Genomes

April 27, 2016

(Nature) – One of the world’s largest pharmaceutical companies has launched a massive effort to compile genome sequences and health records from two million people over the next decade. In doing so, AstraZeneca and its collaborators hope to unearth rare genetic sequences that are associated with disease and with responses to treatment. It’s an unprecedented number of participants for this type of study, says Ruth March, vice-president and head of personalized health care and biomarkers at AstraZeneca, which is headquartered in London. “That’s necessary because we’re going to be looking for very rare differences among individuals.”

The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.